Rhabdomyolysis Associated with Fluoroquinolones;Rhabdomyolysis and Myopathy with Combined Therapy for Hyperlipidemia;Incidence of Rhabdomyolysis in Hospitalized Patients and Conflict of Interest Controversy;Abdominal Cramping Associated with Prostaglandin Analog Ophthalmic Solution;Pioglitazone-Induced Heart Failure in a Patient with Normal Left Ventricular Function;Hearing Loss Due to Clarithromycin;Hyponatremia with Bupropion – Verified by Rechallenge;Dystonia Associated with Gabapentin
Restricted accessResearch articleFirst published online March, 2005
Rhabdomyolysis Associated with Fluoroquinolones;Rhabdomyolysis and Myopathy with Combined Therapy for Hyperlipidemia;Incidence of Rhabdomyolysis in Hospitalized Patients and Conflict of Interest Controversy;Abdominal Cramping Associated with Prostaglandin Analog Ophthalmic Solution;Pioglitazone-Induced Heart Failure in a Patient with Normal Left Ventricular Function;Hearing Loss Due to Clarithromycin;Hyponatremia with Bupropion – Verified by Rechallenge;Dystonia Associated with Gabapentin
The purpose of this feature is to heighten awareness of specific adverse drug reactions (ADRs), to discuss methods of prevention, and to promote reporting of ADRs to the FDA's medWatch program (800-FDA-1088). If you have reported an interesting preventable ADR to medWatch, please consider sharing the account with our readers.
GrahamD.J., StaffaJ.A., ShatinD.Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.JAMA.2004; 292(21): 2585–2590.
3.
PsatyB.M., FurbergC.D., RayW.A.Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivistatin and risk of rhabdomyolysis.JAMA.2004; 292(21): 2622–2631.
4.
StromB.L.Potential for conflict of interest in the evaluation of suspected adverse drug reactions: a counterpoint.JAMA.2004; 292(21): 2643–2646.
5.
PiorkowskiJ.D.Jr.Bayer's response to “potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivistatin and risk of rhabdomyolysis.”JAMA.2004; 292(21): 2655–2657.
6.
PsatyB.M., FurbergC.D., RayW.A.Authors’ reply to Bayer's response to “Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivistatin and risk of rhabdomyolysis.”JAMA.2004; 292(21): 2658–2659.
7.
FontanarosaP.B., RennieD., DeAngelisC.D.Postmarketing surveillance – lack of vigilance, lack of trust.JAMA.2004; 292(21): 2647–2650.
8.
LeeY.C.Abdominal cramp as an adverse effect of travoprost.Am J Ophthamol.2005; 139(1): 202–203.
9.
ShahM., KolandaiveluA., FearonW.F.Pioglitazone-induced heart failure despite normal left ventricular function.Am J Med.2004; 117(12): 973–974.
10.
ShusterJ.ISMP adverse drug reactions.Hosp Pharm.2004; 39(7): 624–625.
11.
CoulstonJ., BalaratnamN.Irreversible sensorineural hearing loss due to clarithromycin.Postgrad Med J.2005; 81: 58–59.
12.
BagleyS.C., YaegerD.Hyponatremia associated with bupropion, a case verified by rechallenge.J Clin Psychopharmacol.2005; 25(1): 98–99.
